These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1778109)

  • 1. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide.
    Aoki Y
    Diabetes Res Clin Pract; 1991 Dec; 14(3):165-73. PubMed ID: 1778109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endogenous insulin secretion was suppressed during insulin therapy in NIDDM patients.
    Murayama Y; Kawai K; Nakamura S; Yamashita K
    Diabetes Res Clin Pract; 1990; 9(2):129-36. PubMed ID: 2198153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood ketone bodies in NIDDM: relationship with diabetic control and endogenous insulin secretion.
    Suzuki M; Kosegawa I; Miura S; Negishi K; Itabashi A; Katayama S; Ishii J; Kamata S; Fujita C
    Diabetes Res; 1991 Sep; 18(1):11-7. PubMed ID: 1823641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects.
    Bogardus C; Lillioja S; Howard BV; Reaven G; Mott D
    J Clin Invest; 1984 Oct; 74(4):1238-46. PubMed ID: 6384267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reevaluation of urine C-peptide as measure of insulin secretion.
    Tillil H; Shapiro ET; Given BD; Rue P; Rubenstein AH; Galloway JA; Polonsky KS
    Diabetes; 1988 Sep; 37(9):1195-201. PubMed ID: 3044885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment.
    Lindström T; Arnqvist HJ; Ludvigsson J; von Schenck HH
    Acta Endocrinol (Copenh); 1992 Jun; 126(6):477-83. PubMed ID: 1642079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion.
    Lev-Ran A; Hwang D; Barseghian G; Hill LR
    Diabete Metab; 1986 Dec; 12(6):325-8. PubMed ID: 3545932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
    Matsumoto K; Akazawa S; Abiru N; Yano M; Ishibasi M; Uotani S; Matsuo H; Kawasaki E; Yamasaki H; Yamamoto H
    Diabetes Res Clin Pract; 1994 Dec; 26(2):129-35. PubMed ID: 7705194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes.
    Bowman P; McDonald TJ; Shields BM; Knight BA; Hattersley AT
    Diabet Med; 2012 Jan; 29(1):90-3. PubMed ID: 21883437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the alteration of the concentration of C-peptide in 24-h urine according to the combination patterns of hypoglycemic agents in type 2 diabetes patients.
    Jung CH; Rhee EJ; Kim ER; Kim SY; Shin HS; Lee WY; Oh KW; Park SW; Kim SW
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S208-12. PubMed ID: 17459509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes.
    Okuno Y; Sakaguchi K; Komada H; Hashimoto N; Hirota Y; Nakamura T; Ogawa W; Seino S
    Kobe J Med Sci; 2013 Apr; 59(2):E44-53. PubMed ID: 23756662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion.
    Wauters M; Considine RV; Yudkin JS; Peiffer F; De Leeuw I; Van Gaal LF
    Horm Metab Res; 2003 Feb; 35(2):92-6. PubMed ID: 12734788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
    Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
    Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
    Albareda M; Rigla M; Rodríguez-Espinosa J; Caballero A; Chico A; Cabezas R; Carreras G; Pérez A
    Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes.
    Chung JO; Cho DH; Chung DJ; Chung MY
    Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment.
    Valensi P; Moura I; Le Magoarou M; Pariès J; Perret G; Attali JR
    Diabetes Metab; 1997 Feb; 23(1):51-7. PubMed ID: 9059766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.